Phage Cocktails for Farm Animals Face Tough Chemistry on the Way to the Gut

Bacteriophages, the viruses that infect and kill bacteria, have long been promoted as a biological answer to one of the most pressing problems in modern food production: the relentless rise of antimicrobial resistance among veterinary pathogens. A comprehensive review published in Frontiers in Veterinary Science now takes a hard look at why this promise has been so difficult to translate from the laboratory bench to the barnyard. The analysis, which synthesizes physicochemical constraints and therapeutic outcomes across poultry, swine, ruminants, and aquaculture, argues that the fate of a therapeutic phage is decided less by its ability to lyse bacteria in a petri dish than by its capacity to survive a gauntlet of hostile environments on the way to the site of infection.

The core difficulty is straightforward in principle and formidable in practice. Orally administered phages must pass through gastric acid, digestive enzymes, and bile salts before they can reach bacterial targets in the intestine. Each of these barriers can strip orders of magnitude from the infectious titer of a phage preparation. Gastric acidity in monogastric animals can denature phage capsid proteins and depolymerize structural components, while proteases and lipases attack the virion directly. Bile salts disrupt membranes and envelope-associated structures in sensitive phages. By the time an unprotected cocktail reaches the intestinal lumen, the effective multiplicity of infection may have collapsed far below the threshold needed to suppress a pathogen population, producing the frustrating pattern of strong in vitro bacteriolysis followed by inconsistent in vivo efficacy that has dogged the field.

Feed processing adds a further layer of stress that is easy to overlook. Much of modern animal agriculture delivers therapeutics through pelleted feed, and the thermal and mechanical forces involved in pelleting can be devastating to phage viability. The review emphasizes that thermal stress during feed manufacturing, together with osmotic fluctuations encountered during storage and rehydration in the gastrointestinal tract, contributes substantially to the loss of orally administered phage titers. A cocktail that is stable for months in a refrigerated liquid stock may lose most of its infectivity within hours of being incorporated into a standard production feed. Any formulation strategy intended for food animals must therefore be validated not only against digestive physiology but against the industrial conditions under which the product will actually be delivered.

Formulation science offers a growing toolbox of protective technologies, and the review systematically examines the leading candidates. Lyophilization and spray-drying convert liquid phage stocks into dry powders with markedly improved shelf life and heat tolerance, making them attractive for feed supplementation. Encapsulation strategies go further by surrounding virions with physical barriers that dissolve only under specific conditions. Alginate and chitosan matrices have been widely studied because they shield phages from acid while releasing their payload as pH rises in the intestine. Lipid nanoparticles and hydrogel systems extend this logic, offering tunable release kinetics and additional protection against enzymatic and osmotic insults. Each technology imposes trade-offs, however: encapsulation can reduce the initial burst of phage release, add cost and complexity to manufacturing, and in some cases compromise the very stability parameters it is meant to improve.

Delivery route shapes biopharmaceutical requirements in ways that formulation must accommodate. The review compares oral, parenteral, intramammary, and aerosol delivery and finds that each places distinct demands on the product. Oral delivery, the most practical route for large flocks and herds, demands acid and enzyme protection and resistance to feed processing. Intramammary administration for bovine mastitis bypasses much of the digestive gauntlet but requires formulations that maintain phage stability in the udder environment and achieve adequate distribution through glandular tissue. Aerosol delivery, of particular interest for respiratory pathogens in poultry and swine, depends on droplet size, mucociliary clearance, and the ability of phages to persist on mucosal surfaces. Parenteral routes raise their own questions about pharmacokinetic distribution and the rapid clearance of virions by the reticuloendothelial system. No single route or formulation can serve all therapeutic scenarios, which argues for product development that begins with the target species and disease rather than with the phage.

The species-specific physiology of production animals emerges as a decisive variable. In poultry and swine, acid-resistant encapsulation strategies can reasonably be expected to protect phages through the stomach and release them in the intestine, and therapeutic studies reviewed in the article show that formulations optimized for gastrointestinal physiology can significantly reduce target bacterial loads and mortality rates. Ruminants present a fundamentally different challenge. The forestomach system, with its dense and metabolically active microbiome, can inactivate phages or trigger premature release from encapsulation matrices before the dose ever reaches the lower gastrointestinal tract. The review highlights a remarkable divergence here: methods that succeed in monogastric animals may fail entirely in cattle and other ruminants because the rumen environment and its microbial community act as an additional, and poorly characterized, barrier. Designing phage products for ruminants therefore requires an understanding of ruminal transit, microbial interactions, and matrix degradation that goes well beyond standard acid protection.

Therapeutic outcomes across sectors reinforce this species-dependence. In poultry, where oral delivery via water or feed is logistically feasible at scale, well-formulated cocktails have achieved meaningful reductions in pathogens such as Salmonella and Escherichia coli, with corresponding decreases in mortality. In swine, comparable successes have been reported against enteric pathogens, though again hinging on formulation choices matched to gastric conditions. In aquaculture, where phages can be delivered directly into the water column, the constraints shift toward salinity, ultraviolet exposure, and dilution. What unites the failure cases, the review argues, is not a flaw in the phages themselves but a mismatch between in vitro stability data and the pharmacokinetic realities of the treated animal. Trials that measure phage persistence only under laboratory conditions cannot predict whether infectious virions will arrive at the site of infection in sufficient numbers and at the right time.

This gap between laboratory characterization and in vivo performance points to the review’s central methodological recommendations. The authors call for standardized assays of phage titer that can be reproduced across different laboratories, a prerequisite for comparing results and building regulatory dossiers. They further advocate the development of physiologically based pharmacokinetic and pharmacodynamic models capable of predicting the temporal and spatial dynamics of phage-bacteria interactions within the animal body. Such models would allow formulators to estimate how much phage survives each barrier, when and where it is released, and whether the resulting concentration exceeds the inoculum-dependent threshold needed to tip the balance against the pathogen population. In parallel, the review stresses the need for well-defined regulatory processes, since the current patchwork of oversight for biological veterinary products creates uncertainty that discourages investment in commercial development.

For a field racing to provide alternatives to antibiotics in food animal production, the roadmap offered here is sobering but constructive. Phage cocktails remain one of the most promising non-antibiotic strategies available, capable of narrowing host range to pathogens while sparing beneficial microbiota and leaving no persistent chemical residues in meat or milk. The review’s synthesis suggests that the next generation of products will be defined as much by formulation chemistry and pharmacokinetic modeling as by phage biology. Rational design, in this vision, means selecting phages not only for lytic potency and complementary resistance profiles but for stability under the specific thermal, chemical, and microbial conditions of the target species, delivery route, and feed system. If those constraints are met, the authors argue, bacteriophage therapy can move from promising case reports toward reliable tools that measurably reduce antibiotic dependence in veterinary medicine, protecting both animal welfare and the efficacy of the antimicrobials that human and animal health still share.

Subject of Research: Physicochemical stability and delivery of bacteriophage cocktails for treating bacterial infections in food-producing animals

Article Title: Formulation, stability, and delivery of bacteriophage cocktails in veterinary medicine: a review of physicochemical constraints and therapeutic outcomes in production animals

Article References: Muneeb, M., Tharwat, M., Shaukat, A., Nassar, N., Qu, Y., Khan, A. Y., & Alshanbari, F. A. (2026). Formulation, stability, and delivery of bacteriophage cocktails in veterinary medicine: a review of physicochemical constraints and therapeutic outcomes in production animals. Frontiers in Veterinary Science, 13, Article 1988130. https://doi.org/10.3389/fvets.2026.1988130

Image Credits: AI Generated

DOI: 10.3389/fvets.2026.1988130

Keywords: bacteriophage therapy, antimicrobial resistance, veterinary medicine, phage cocktails, encapsulation, livestock, poultry, swine, ruminants, feed pelleting, pharmacokinetics, food safety